Alzheimer Disease Pathology As a Host Response
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Identification of amyloid-beta and tau as the major protein components of senile plaques and neurofibrillary tangles, respectively, led to an exponential increase in investigations of these proteins and their corresponding metabolic pathways in Alzheimer disease (AD). The presumptions inherent in most studies and in the dogma of the amyloid cascade concept are that these hallmark lesions in AD brains contain molecules that drive the disease process, and that the proteinaceous accumulations are themselves toxic. On the other hand, the lesions of AD are, by definition, end-stage, and their relationship to the clinical disease is inconsistent; this has long been known but, generally, has not been acknowledged until relatively recently. Some recent attempts to address the etiology and pathogenesis of AD discard the pathology and focus on the interplay between invisible toxic intermediates, that is, amyloid-beta oligomers and the synapse. The concept that the hallmark lesions may be nontoxic (something we have long suggested) is slowly gaining acceptance. We favor the interpretation that senile plaques and neurofibrillary tangles represent a host response to an upstream pathophysiologic process, and that the therapeutic targeting of lesions, including toxic intermediates, will succeed only in the event that the host response is directly deleterious. Therefore, renewed efforts aimed at elucidating fundamental age-related processes such as oxidative stress and/or inflammatory mediators are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“for example, SPs and NFTs may elicit a host response that contributes to the neurotoxicity of AD.(Castellani et al., 2008)”
From Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease (2009) · cites this paper as Castellani et al., 2008
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“The Braak method for neuropathologic staging described approximately the same time as, CERAD criteria (42) presumes that everyone with a lesion has some degree of AD regardless of clinical signs.”
MethodMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 1×
“Little progress had been made into plaque pathogenesis aside from some ultrastructural details (30) until modern molecular techniques were applied to purified vascular amyloid and amyloid plaque cores (31, 32), and demonstrated a small protein, designated AA, later discovered to be a metabolic product of AA precursor…”
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208 · cited 1×
“In another AD-like model, axonal pathology with accumulation of tau preceded plaque deposition (74), and studies of a P301S tauopathy model demonstrated microglial activation and synapse loss prior to NFT formation (75).”
BackgroundTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 1×
“the stabilization and maintenance of microtubules) combined with a toxic gain of function can compromise axonal transport and contribute to the synaptic degeneration that is now a central theme (22, 73).”
BackgroundTau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014 · cited 2×
“A host of transgenic mouse constructs and their experimental manipulations are also suggested as critical evidence that substantiate the AA hypothesis, although such models may suffer with respect to relevance (44).”
BackgroundAβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.
Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38495-8 · Cited by 1,778 · cited 1×
“Some ultrastructural details of NFTs were subsequently added to literature (16), but it was not until 1986 that NFTs were purified and the microtubule-associated protein tau determined as the major protein component (17).”
BackgroundCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693 · cited 1×
“Little progress had been made into plaque pathogenesis aside from some ultrastructural details (30) until modern molecular techniques were applied to purified vascular amyloid and amyloid plaque cores (31, 32), and demonstrated a small protein, designated AA, later discovered to be a metabolic product of AA precursor…”
Regulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561 · cited 1×
“supernatant fraction after high-speed centrifugation), nonfibrillar AA is the fundamental pathogenic event (63, 64).”
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530
Uber eine eigenartige Erkrankung der Hirnrinde
Alzheimer, A. (1907) · Medical Entomology and Zoology · Cited by 1,503
Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.
Lorenzo, A., & Yankner, B. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12243 · Cited by 1,324 · cited 1×
“It was shown, for example, that toxicity of AA was linked to fibril formation (52).”
BackgroundAxonopathy and Transport Deficits Early in the Pathogenesis of Alzheimer’s Disease
Stokin, G. B., Lillo, C., Falzone, T. L., Brusch, R. G., Rockenstein, E., Mount, S. L., Raman, R., Davies, P., Masliah, E., Williams, D. S., et al. (2005) · Science · doi:10.1126/science.1105681 · Cited by 1,214 · cited 1×
“In another AD-like model, axonal pathology with accumulation of tau preceded plaque deposition (74), and studies of a P301S tauopathy model demonstrated microglial activation and synapse loss prior to NFT formation (75).”
BackgroundTangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease
Giannakopoulos, P., Herrmann, F. R., Bussière, T., Bouras, C., Kövari, E., Perl, D. P., Morrison, J. H., Gold, G., & Hof, P. R. (2003) · Neurology · doi:10.1212/01.wnl.0000063311.58879.01 · Cited by 1,118
Hofman, A., Ott, A., Breteler, M. M., Bots, M. L., Slooter, A. J., van Harskamp, F., van Duijn, C. N., Van Broeckhoven, C., & Grobbee, D. E. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09328-2 · Cited by 1,062 · cited 1×
“Chronic renal failure, like AD, is a common medical illness associated with advanced age, atherosclerosis, and diabetes mellitus (80, 81).”
BackgroundPaired Helical Filaments in Electron Microscopy of Alzheimer's Disease
KIDD, M. (1963) · Nature · doi:10.1038/197192b0 · Cited by 1,012 · cited 2×
“This may well explain why the fibrils survived the decay of cellsI^ (11) The structure of the NFT was further elucidated by Terry (14) in 1963; the same year, Kidd (15) described paired helical filaments.”
BackgroundConsensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Release of Excess Amyloid β Protein from a Mutant Amyloid β Protein Precursor
Cai, X.-D., Golde, T. E., & Younkin, S. G. (1993) · Science · doi:10.1126/science.8424174 · Cited by 913 · cited 1×
“Whereas the AA1-42 species is commonly accepted as Bpathogenic,^ and the increased ratio of AA1-42/AA1-40 in familial AD is posited as a central piece of evidence (37, 47, 48), more recent studies show that the increased ratio is due to a marked decrease in AA1-40 (49, 50).”
BackgroundPresenilin is required for activity and nuclear access of Notch in Drosophila
Struhl, G., & Greenwald, I. (1999) · Nature · doi:10.1038/19091 · Cited by 796
über eigenartige Krankheitsfälle des späteren Alters
Alzheimer, A. (1911) · Zeitschrift für die gesamte Neurologie und Psychiatrie · doi:10.1007/bf02866241 · Cited by 710
Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease
Jacobsen, J. S., Wu, C.-C., Redwine, J. M., Comery, T. A., Arias, R., Bowlby, M., Martone, R., Morrison, J. H., Pangalos, M. N., Reinhart, P. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600948103 · Cited by 701
Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676
Neuropathology of Cognitively Normal Elderly
Knopman, D. S., Parisi, J. E., Salviati, A., Floriach-Robert, M., Boeve, B. F., Ivnik, R. J., Smith, G. E., Dickson, D. W., Johnson, K. A., Petersen, L. E., et al. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.11.1087 · Cited by 674 · cited 1×
“Similarly, large amounts of amyloid and varying plaque types may be found in the brains of the cognitively intact elderly (60, 62).”
BackgroundBerg, L., McKeel, D. W., Miller, J. P., Storandt, M., Rubin, E. H., Morris, J. C., Baty, J., Coats, M., Norton, J., Goate, A. M., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.326 · Cited by 657
Identification of normal and pathological aging in prospectively studied nondemented elderly humans
Dickson, D. W., Crystal, H. A., Mattiace, L. A., Masur, D. M., Blau, A. D., Davies, P., Yen, S.-H., & Aronson, M. K. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90027-u · Cited by 643 · cited 1×
“Similarly, large amounts of amyloid and varying plaque types may be found in the brains of the cognitively intact elderly (60, 62).”
BackgroundInvolvement of oxidative stress in Alzheimer disease
Nunomura, A., Castellani, R. J., Zhu, X., Moreira, P. I., Perry, G., & Smith, M. A. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000228136.58062.bf · Cited by 611 · cited 1×
“With the mindset that the pathologic lesions and the complex biochemical cascades that accompany them are a response to more fundamental age-associated upstream processes such as oxidative stress (78) or inflammation (79), several problematic aspects of AD pathology become less so (Fig.”
BackgroundSelf-citationWang, J., Dickson, D. W., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7085 · Cited by 567
Amyloid‐β Deposition in Alzheimer Transgenic Mice Is Associated with Oxidative Stress
Smith, M. A., Hirai, K., Hsiao, K., Pappolla, M. A., Harris, P. L. R., Siedlak, S. L., Tabaton, M., & Perry, G. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70052212.x · Cited by 547 · cited 1×
“It has also been shown experimentally that transgenic manipulation of AA mice to ablate production of AA (whether it be monomer, n-, or fibril) fails to rescue the cognitive deficit (71).”
BackgroundSelf-citationNeocortical Neurofibrillary Tangles Correlate With Dementia Severity in Alzheimer's Disease
Bierer, L. M., Hof, P. R., Purohit, D. P., Carlin, L., Schmeidler, J., Davis, K. L., & Perl, D. P. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540250089017 · Cited by 514
Neurogenic phenotypes and altered Notch processing in Drosophila Presenilin mutants
Ye, Y., Lukinova, N., & Fortini, M. E. (1999) · Nature · doi:10.1038/19096 · Cited by 489
Presenilin clinical mutations can affect γ‐secretase activity by different mechanisms
Bentahir, M., Nyabi, O., Verhamme, J., Tolia, A., Horré, K., Wiltfang, J., Esselmann, H., & De Strooper, B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03578.x · Cited by 415 · cited 1×
“Whereas the AA1-42 species is commonly accepted as Bpathogenic,^ and the increased ratio of AA1-42/AA1-40 in familial AD is posited as a central piece of evidence (37, 47, 48), more recent studies show that the increased ratio is due to a marked decrease in AA1-40 (49, 50).”
BackgroundMolecular mapping of alzheimer‐type dementia in Down's syndrome
Prasher, V. P., Farrer, M. J., Kessling, A. M., Fisher, E. M. C., West, R. J., Barber, P. C., & Butler, A. C. (1998) · Annals of Neurology · doi:10.1002/ana.410430316 · Cited by 414
THE FINE STRUCTURE OF NEUROFIBRILLARY TANGLES IN ALZHEIMERʼS DISEASE
Terry, R. D. (1963) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-196310000-00005 · Cited by 403 · cited 2×
“This may well explain why the fibrils survived the decay of cellsI^ (11) The structure of the NFT was further elucidated by Terry (14) in 1963; the same year, Kidd (15) described paired helical filaments.”
BackgroundNeurons May Live for Decades with Neurofibrillary Tangles
Morsch, R., Simon, W., & Coleman, P. D. (1999) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199902000-00008 · Cited by 370 · cited 1×
“The fact that neurons with NFTs (and presumably tau oligomers) survive for decades (76) and show intact microtubules (77) argues against this notion.”
BackgroundApoptosis mediated neurotoxicity induced by chronic application of β amyloid fragment 25–35
Forloni, G., Chiesa, R., Smiroldo, S., Verga, L., Salmona, M., Tagliavini, F., & Angeretti, N. (1993) · NeuroReport · doi:10.1097/00001756-199305000-00015 · Cited by 341 · cited 1×
“Amyloid-A has been shown to be toxic in vitro by a variety of mechanisms, including induction of apoptosis (53), promotion of inflammatory mediators (54), and an accelerant of oxidative stress (55).”
BackgroundThe Roles of Cyclin-dependent Kinase 5 and Glycogen Synthase Kinase 3 in Tau Hyperphosphorylation
Plattner, F., Angelo, M., & Giese, K. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603469200 · Cited by 340
Evidence that Aβ42 is the real culprit in alzheimer's disease
Younkin, S. G. (1995) · Annals of Neurology · doi:10.1002/ana.410370303 · Cited by 333
Kumar-Singh, S., Theuns, J., Van Broeck, B., Pirici, D., Vennekens, K., Corsmit, E., Cruts, M., Dermaut, B., Wang, R., & Van Broeckhoven, C. (2006) · Human Mutation · doi:10.1002/humu.20336 · Cited by 323 · cited 1×
“Whereas the AA1-42 species is commonly accepted as Bpathogenic,^ and the increased ratio of AA1-42/AA1-40 in familial AD is posited as a central piece of evidence (37, 47, 48), more recent studies show that the increased ratio is due to a marked decrease in AA1-40 (49, 50).”
BackgroundMicrotubule Reduction in Alzheimer's Disease and Aging Is Independent of τ Filament Formation
Cash, A. D., Aliev, G., Siedlak, S. L., Nunomura, A., Fujioka, H., Zhu, X., Raina, A. K., Vinters, H. V., Tabaton, M., Johnson, A. B., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64296-4 · Cited by 307 · cited 1×
“The fact that neurons with NFTs (and presumably tau oligomers) survive for decades (76) and show intact microtubules (77) argues against this notion.”
BackgroundSelf-citationEarly onset familial Alzheimer’s disease: Mutation frequency in 31 families
Janssen, J. C., Beck, J. A., Campbell, T. A., Dickinson, A., Fox, N. C., Harvey, R. J., Houlden, H., Rossor, M. N., & Collinge, J. (2003) · Neurology · doi:10.1212/01.wnl.0000042088.22694.e3 · Cited by 301 · cited 1×
“Given the association between early-onset disease and germline mutations (26, 27), one might also suggest that AD, or presenile dementia, is essentially familial early-onset AD, whereas an arguably different process, Bsenile dementia,^ refers essentially to sporadic disease.”
BackgroundDiabetes Mellitus and Risk of Developing Alzheimer Disease: Results From the Framingham Study
Akomolafe, A., Beiser, A., Meigs, J. B., Au, R., Green, R. C., Farrer, L. A., Wolf, P. A., & Seshadri, S. (2006) · Archives of Neurology · doi:10.1001/archneur.63.11.1551 · Cited by 282 · cited 1×
“Chronic renal failure, like AD, is a common medical illness associated with advanced age, atherosclerosis, and diabetes mellitus (80, 81).”
BackgroundMicrotubule-Associated Protein Tau
Yen, S.-H., Nacharaju, P., Ko, L.-W., Kenessey, A., & Liu, W.-K. (1998) · Handbook of the Aging Brain · doi:10.1016/b978-012734610-6/50012-9 · Cited by 282
The significance of neuroinflammation in understanding Alzheimer’s disease
Eikelenboom, P., Veerhuis, R., Scheper, W., Rozemuller, A. J. M., van Gool, W. A., & Hoozemans, J. J. M. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0575-6 · Cited by 262 · cited 1×
“Amyloid-A has been shown to be toxic in vitro by a variety of mechanisms, including induction of apoptosis (53), promotion of inflammatory mediators (54), and an accelerant of oxidative stress (55).”
BackgroundHernández, F., & Avila, J. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7220-x · Cited by 262
Galvan, V., Gorostiza, O. F., Banwait, S., Ataie, M., Logvinova, A. V., Sitaraman, S., Carlson, E., Sagi, S. A., Chevallier, N., Jin, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509695103 · Cited by 239
The case described by Alois Alzheimer in 1911
Möller, H.-J., & Graeber, M. B. (1998) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060050027 · Cited by 224
Dineley, K. T., Xia, X., Bui, D., Sweatt, J. D., & Zheng, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200164200 · Cited by 212
Voskarides, K., Damianou, L., Neocleous, V., Zouvani, I., Christodoulidou, S., Hadjiconstantinou, V., Ioannou, K., Athanasiou, Y., Patsias, C., Alexopoulos, E., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007040444 · Cited by 209 · cited 1×
“We might then, in turn, note that rare cases of early-onset familial glomerulosclerosis exist, some of which have mutations in Type IV collagen (82).”
BackgroundThe synaptic Aβ hypothesis of Alzheimer disease
Tanzi, R. E. (2005) · Nature Neuroscience · doi:10.1038/nn0805-977 · Cited by 206
Wolfe, M. S., De Los Angeles, J., Miller, D. D., Xia, W., & Selkoe, D. J. (1999) · Biochemistry · doi:10.1021/bi991080q · Cited by 202
Finckh, U., Müller-Thomsen, T., Mann, U., Eggers, C., Marksteiner, J., Meins, W., Binetti, G., Alberici, A., Hock, C., Nitsch, R. M., et al. (2000) · The American Journal of Human Genetics · doi:10.1086/302702 · Cited by 194 · cited 1×
“Given the association between early-onset disease and germline mutations (26, 27), one might also suggest that AD, or presenile dementia, is essentially familial early-onset AD, whereas an arguably different process, Bsenile dementia,^ refers essentially to sporadic disease.”
BackgroundUltrastructure of Neurofibrillary Tangles in Steele-Richardson-Olszewski Syndrome
Tellez-Nagel, I., & Wisniewski, H. M. (1973) · Archives of Neurology · doi:10.1001/archneur.1973.00490290064007 · Cited by 186 · cited 1×
“Some ultrastructural details of NFTs were subsequently added to literature (16), but it was not until 1986 that NFTs were purified and the microtubule-associated protein tau determined as the major protein component (17).”
BackgroundThe Seminal Role of β-Amyloid in the Pathogenesis of Alzheimer Disease
Joachim, C. L., & Selkoe, D. J. (1992) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199205000-00003 · Cited by 182
Amyloid-β in Alzheimer Disease: The Null versus the Alternate Hypotheses
Lee, H., Zhu, X., Castellani, R. J., Nunomura, A., Perry, G. L., & Smith, M. A. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.114009 · Cited by 157
Self-citationCrystal, H. A., Dickson, D., Davies, P., Masur, D., Grober, E., & Lipton, R. B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.5.713 · Cited by 152 · cited 1×
“^ Indeed, in a recent study, the diagnosis of Bdementia of unknown etiology^ approached 50% in nonagenarians (39).”
BackgroundAmyloid β-peptide and oxidative cellular injury in Alzheimer’s disease
Mark, R. J., Blanc, E. M., & Mattson, M. P. (1996) · Molecular Neurobiology · doi:10.1007/bf02755589 · Cited by 146
Neuropathology of Alzheimer disease: pathognomonic but not pathogenic
Castellani, R. J., Lee, H., Zhu, X., Nunomura, A., Perry, G. L., & Smith, M. A. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0071-y · Cited by 141 · cited 8×
“chronic renal failure, chronic liver disease, interstitial lung disease, neuromuscular disease), the pathologic findings invariably become less specific with increased disease duration (6).”
BackgroundInfluentialSelf-citationAlzheimer's disease: A conceptual history
Berríos, G. E. (1990) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.930050603 · Cited by 136 · cited 2×
“This, and the fact that plaques were a known component of senile dementia at that time (10), suggests that the NFT was the more intriguing lesion, so much so that Alzheimer spent considerable time and effort illustrating NFTs and their variations (11).”
BackgroundTau Aggregation and Toxicity in a Cell Culture Model of Tauopathy
Bandyopadhyay, B., Li, G., Yin, H., & Kuret, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700192200 · Cited by 133 · cited 1×
“Toxicity of phosphorylated tau is also said to be linked to its aggregated state with similar properties in vitro (56).”
BackgroundDisease modifying therapy for AD?1
Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117
Pathological tau: a loss of normal function or a gain in toxicity?
Trojanowski, J. Q., & Lee, V. M. ‐. (2005) · Nature Neuroscience · doi:10.1038/nn0905-1136 · Cited by 100 · cited 1×
“the stabilization and maintenance of microtubules) combined with a toxic gain of function can compromise axonal transport and contribute to the synaptic degeneration that is now a central theme (22, 73).”
BackgroundEarly-onset familial Alzheimer's disease: Mutation frequency in 31 families
Janssen, J. C., Beck, J. A., Campbell, T., Dickinson, A., Fox, N. C., Harvey, R. J., Houlden, H., Rosser, M. N., & Collinge, J. (2002) · UCL Discovery (University College London) · Cited by 88
Set back to Alzheimer vaccine studies
Birmingham, K. E., & Frantz, S. (2002) · Nature Medicine · doi:10.1038/nm0302-199b · Cited by 86 · cited 1×
“Indeed, despite considerable time, expenditure, and repeated modifications, lesion-based therapies continue to be disappointing (3, 4), whereas simple enhancement of neurotransmission remains the only modestly useful therapy (5).”
BackgroundCommon Inflammatory Mechanisms in Lewy Body Disease and Alzheimer Disease
Mrak, R. E., & Griffin, W. S. T. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31812503e1 · Cited by 85 · cited 1×
“With the mindset that the pathologic lesions and the complex biochemical cascades that accompany them are a response to more fundamental age-associated upstream processes such as oxidative stress (78) or inflammation (79), several problematic aspects of AD pathology become less so (Fig.”
BackgroundThe ultrastructure of senile plaques.
Luse, S. A., & Smith, K. R. (1964) · PubMed Central · Cited by 66
On causative theories in Alzheimer's disease
Glenner, G. G. (1985) · Human Pathology · doi:10.1016/s0046-8177(85)80078-2 · Cited by 64
Wilkins, R. H., & Brody, I. A. (1969) · Archives of Neurology · doi:10.1001/archneur.1969.00480130123013 · Cited by 62
Jicha, G. A., Petersen, R. C., Knopman, D. S., Boeve, B. F., Smith, G. E., Geda, Y. E., Johnson, K. A., Cha, R., DeLucia, M. W., Braak, H., et al. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000225312.11858.57 · Cited by 53
Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?
Castellani, R. J., Zhu, X., Lee, H., Moreira, P. I., Perry, G. L., & Smith, M. A. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.5.473 · Cited by 48 · cited 1×
“Indeed, despite considerable time, expenditure, and repeated modifications, lesion-based therapies continue to be disappointing (3, 4), whereas simple enhancement of neurotransmission remains the only modestly useful therapy (5).”
BackgroundSelf-citationMICROTUBULE ASSOCIATED PROTEIN TAU
Grundke, I., & Iqbal, K. (1989) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-198905000-00097 · Cited by 46
New V272A presenilin 1 mutation with very early onset subcortical dementia and parkinsonism
Jimenez‐Escrig, A., Rabano, A., Guerrero, C., Simon, J., Barquero, M. S., Güell, I., Ginestal, R. C., Montero, T., & Orensanz, L. (2004) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00865.x · Cited by 45 · cited 1×
“Presentations such as cerebral hemorrhage without dementia, spastic paraparesis with delayed dementia, subcortical dementia with Parkinsonism, and seizures (6, 45, 46) clearly differ from sporadic AD.”
BackgroundShrimpton, A. E., Schelper, R. L., Linke, R. P., Hardy, J., Crook, R., Dickson, D. W., Ishizawa, T., & Davis, R. L. (2007) · Neuropathology · doi:10.1111/j.1440-1789.2007.00766.x · Cited by 40 · cited 1×
“Presentations such as cerebral hemorrhage without dementia, spastic paraparesis with delayed dementia, subcortical dementia with Parkinsonism, and seizures (6, 45, 46) clearly differ from sporadic AD.”
BackgroundAmyloid and Alzheimer's disease—Cause or effect?
Yankner, B. A. (1989) · Neurobiology of Aging · doi:10.1016/0197-4580(89)90101-2 · Cited by 33
Fuller, S. C. (1907) · American Journal of Psychiatry · doi:10.1176/ajp.63.4.415 · Cited by 21 · cited 3×
“The lengthy description of Bneurofibrils^ by Fuller (8) several months prior to Alzheimer`s description of Auguste D. has been suggested as evidence that the NFT was also known prior to Alzheimer`s description.”
BackgroundInfluentialAmyloid-β Vaccination: Testing the Amyloid Hypothesis?
Lee, H., Zhu, X., Nunomura, A., Perry, G. L., & Smith, M. A. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060633 · Cited by 20
Self-citationAlzheimer's disease — from cause to cure?
Vines, G. (1993) · Trends in biotechnology · doi:10.1016/0167-7799(93)90122-p · Cited by 13
MICROTUBULE ASSOCIATED PROTEIN TAU
Ruben, G. C., Grundke, I., Iqbal, K., & Wisniewski, H. M. (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802030-00041 · Cited by 10
Alzheimer's disease. New insights into its cause lead to new drug strategies.
Nash, J. M. (2001) · PubMed · Cited by 9
Mutation Identified as a Possible Cause of Alzheimer's Disease
Marx, J. L. (1991) · Science · doi:10.1126/science.1900373 · Cited by 7 · cited 1×
“This finding initiated a substantial focus on tau pathophysiology; however, because the identification of tau in NFTs occurred approximately 2 years after the identification of amyloid-A (AA) in plaques, and because Down syndrome and familial Alzheimer disease (AD) had a genetic link to AA, it is not surprising that A…”
Background(1999) · doi:10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m
Self-citation
Research works printed but not linked: 6
- Tomlinson BE . Ageing and the dementias. In: Greenfield JB Adams JH Duchen L , eds. Greenfield's Neuropathology , 5th ed, Oxford, UK: Oxford University Press, 1992:1284–410
- Maurer K Maurer U . Alzheimer's Disease: The Life of a Physician and the Career of a Disease . Chichester, West Sussex, UK: Columbia University Press, 2003
- Beljahow, 1889, Pathological changed in the brain in dementia senilis, J Mental Sci, 35, 261
- Simchowicz, 1924, Sur la signification des plaques seniles et sur la formule senile de l'ecorce cerebrale, Rev Neurol, 31, 221
- Marinesco, 1911, Sur la structure des plaques dites seniles dans l'ecorce cerebrale des sujets ages et atteints d'affections mentales, Comptes Rendus Seances Soc Biol Fil, 70, 606
- Divry, 1927, Etude histo-chimique des plaques seniles, J Belge Neurol Psychiatr, 27, 643
Cited by
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
“We note that there are publications contending that CPC data argue against a deleterious role for AD pathologic changes (i.e. that they may be an ‘‘epiphenomenon’’ of aging) and that the disease should not necessarily be defined by their presence (62 Y 68).”
BackgroundSelf-citationA critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661
Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship
Nelson, P. T., Braak, H., & Markesbery, W. R. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181919a48 · Cited by 643
“These considerations help explain why some prior studies have shown apparent general discrepancies with regard to the correlation of extent of pathology and the severity of premortem cognitive decline (1).”
BackgroundInfluentialCastellani, R. J., Rolston, R. K., & Smith, M. A. (2010) · Disease-a-Month · doi:10.1016/j.disamonth.2010.06.001 · Cited by 519
Self-citation
Metadata
- Authors
- Castellani, R. J., Lee, H.-G., Zhu, X., Perry, G., & Smith, M. A.
- Affiliations
- University of Maryland, Baltimore (US)
- Case Western Reserve University (US)
- The University of Texas at San Antonio (US)
- Corresponding author
- Castellani, Rudy J.
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-06
- Volume
- 67
- Issue
- 6
- Pages
- 523-531
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- PMC
- PMC2763411
- OpenAlex
- W1987793916
- Cited by
- 171
- References
- 88
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 11 · 2019: 6 · 2018: 6 · 2017: 10 · 2016: 7 · 2015: 7 · 2014: 18 · 2013: 7 · 2012: 17
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Neuropathology & Experimental Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01AG026151)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, host response, amyloid-beta, tau protein, amyloid plaques, neurofibrillary tangles, amyloid hypothesis, amyloid-beta oligomers, synapses, oxidative stress, neuroinflammation, pathogenesis
- MeSH terms
- Aging, Alzheimer Disease, Animals, Humans, Inflammation, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Oxidative Stress, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.